• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Shelf Life for Passive Implantable Medical Devices: Draft Amendment Released

Shelf Life for Passive Implantable Medical Devices: Draft Amendment Released

Monday, 26 July 2021 / Published in Medical Device, News, NMPA Registration in China

Shelf Life for Passive Implantable Medical Devices: Draft Amendment Released

On June 10, 2021, the CMDE (Center for Medical Device Evaluation) of the NMPA (National Medical Products Administration) released the 2021 draft amendment of the guiding principles for the shelf-life of passive implantable medical device for registration and filing. The previous version of the guiding principles was issued in May 2017.  

Highlights

  • Consider how to set shelf life from the initial stage of the product development, and how to confirm the shelf life of the product continuously before and after selling into the market.
  • Validation tests of shelf life of medical devices usually include accelerated stability test, real-time stability test, etc.
  • The accelerated stability test design is based on the assumption that the chemical reactions involved in material deterioration follow the Arrhenius reaction rate function. However, not all the chemical reaction rates of materials conform to this function with the change of temperature. Many accelerated aging tests used in medical devices of polymer materials have been estimated based on the zero-order, first-order and pseudo-first-order chemical reactions of this equation.
  • Registered applicants are advised to set up multiple test observation time points (normally not less than 3) during the accelerated aging test. The zero-time performance data can be used as the reference index of the test items. The last observation point should be at least the same as the expected shelf life. Considering the complexity of changes in the real-world environment, it is recommended to set observation points longer than expected to declare shelf life.
  • The shelf life verification test of medical devices should be carried out with the same final products as the conventional production, and the packaging without products can be used for the verification of suitable items (such as packing tightness). Validation of the appropriate batch of products may be considered if the differences between batches may affect the results of shelf life verification. After the applicant has fully assessed the product and packaging material characteristics, sterilization process and other influencing factors, one batch of products may be selected for testing when appropriate.

By Colleen Xu. Contact Cisema if you would like to learn more.

Tagged under: Implants

What you can read next

innovative-provisions-for-cosmetics-in-pudong-shanghai
Innovative provisions for cosmetics in Pudong, Shanghai now in force
China medical device quality safety responsibility
China medical device quality and safety responsibility regulations come into force on March 1, 2023
China Regulations on the Supervision and Administration of Children’s Cosmetics (Draft for soliciting opinions)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.